Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 44 for “"Anti-CD19"”.
-
Anti-CD19-konjugierte Zytostatika-Liposomen zur gezielten Therapie der pädiatrischen B-Zell-Leukämie
… vesikuläre Lipid-Nanocarrier, die mit Antikörpern gegen möglichst tumorzellspezifische Oberflächen-Antigene funktionalisiert sind. Dies soll eine gezielte Akkumulation und Freisetzung des verkapselten Wirkstoffs an oder innerhalb der Tumorzellen ermöglichen.<br>Im Rahmen der …
-
EFFECT OF B CELL MODULATION VIA NON-DEPLETING ANTI-CD19 ANTIBODY ON MYOCARDIAL PHYSIOLOGY
… study, we investigated the impact of targeting CD19 on B cell function and cardiac physiology in C57BL6J mice. In vitro treatment of primary mouse splenic B cells with anti-CD19 monoclonal antibody (mAb) induced internalization of surface CD19 on mouse splenic B cells and led to a reduction in B …
-
Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia
… immunotherapies for them are based on anti-CD20 monoclonal antibodies (MAbs). However, CD20 is not expressed on precursor B cell acute lymphoblastic leukemia (pre-B ALL), and CD20 expression is often lost following anti-CD20 immunotherapy. CD19 is a pan B cell membrane antigen that is …
-
Improving persistence of anti-CD19 CAR T cells via overexpression of the IL-21 receptor
Adoptive transfer of anti-CD19 chimeric antigen receptor (CAR) T cells has revolutionized the therapy of relapsed/refractory B-cell precursor ALL. High initial remission rates are nevertheless hampered by a lack of long-term persistence due to T cell exhaustion. Sustained proliferation and …
-
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
… with a specific view on the immunostimulation of anti- CD19/CD20 × CD3 bispecific antibodies (CD19-BsAb and CD20-BsAb, respectively) in this process. Methods: Our published microarray-based gene dataset was used for gene set enrichment analysis, functional annotation and clustering analysis. A …
-
PC3-Feederzell-basierte ex vivo Expansion primärer CAR-NK-Zellen mit anti-CD19-CARs unterschiedlicher Affinität unter Berücksichtigung von Trogozytose
… Rolle. Insbesondere die Zulassung von chimären Antigenrezeptor (CAR)-T-Zelltherapien gegen B-Zell-spezifische Marker wie D19 hat das therapeutische Spektrum erheblich erweitert. Dennoch werden T-Zell-basierte Therapien mit erheblichen Nebenwirkungen assoziiert. Vor diesem Hintergrund rücken …
-
Delineating the apoptotic mechanisms of an anti-CD19 immunotoxin used in combination with the anti-CD20 antibody rituximab against human B-lymphoma cells
<p>The aim was to determine the effect of rituximab and BU12-saporin individually and in combination on B lymphoma cell lines and determine the contribution of complement mediated mechanisms. In an <i>in vitro</i> protein synthesis inhibition assay, using Burkitt’s lymphoma cells, the presence of …
-
Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy
… T cell therapy, but more specifically, chimeric antigen receptor (CAR) expressing T cell transfer, has had notable clinical success particularly against hematological malignancies. Chimeric antigen receptors are synthetic immunoreceptors which can redirect T cells towards varying tumor associated …
-
Αποτελεσματικότητα και ασφάλεια των χιμαιρικών αντιγονικών υποδοχέων Τ-κυττάρων σε ασθενείς με υποτροπιάζουσα/ανθεκτική οξεία λεμφοβλαστική λευχαιμία (ΟΛΛ): μία συστηματική ανασκόπηση
… τυχαιοποιημένων κλινικών μελετών (24 μελέτες με anti-CD19, 2 με anti-CD22, 5 με anti-CD19/CD22 CAR-T κύτταρα) που αφορούν ασθενείς με υποτροπιάζουσα/ανθεκτική Β-ΟΛΛ. Όλες οι κλινικές μελέτες είναι φάσεως 1 ή 2, ανοικτού τύπου, ενώ καμία δεν διέθετε συγκριτική ομάδα ελέγχου. Η κυτταρική θεραπεία …
-
Using RNA-Sequencing to Explore Mechanistic Markers, New Therapeutics, and Immune Imbalance: A Study of Cancer and Autoimmunity Through the Lens of Triple Negative Breast Cancer, Systemic Lupus Erythematosus, and B-Cell Non-Hodgkin's Lymphoma
Cancer and autoimmune diseases both impose a substantial healthcare burden on the US and world populations. In 2016, there were over 17 million cases of cancer, leading to nearly nine million deaths. Additionally, autoimmune diseases cause substantial mortality and morbidity and are present in 3-5% …
-
Establishing a CRISPR/CAS9-mediated double KI of pro-inflammatory IL-18 into HAVCR2 and 19BB3z into TRAC locus to generate persistent and safe CAR-T-cells
… but achieving long-term success with chimeric antigen receptor CAR-T-cells remains a challenge. Anti-CD19 CAR-T-cells have recently been approved by the FDA and EMA for treating relapsed or refractory acute lymphoblastic leukemia (ALL). While initial response rates are high, preventing relapse …
-
Exploring Novel B-cell Specific Immunomodulatory Adjuvants and Future Implications for HIV Vaccines
Eliciting broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus-1 (HIV-1). HIV-1 infects CD4 T cells through its envelope glycoprotein trimer (Env), which is the only virally encoded protein on the viral surface and thus serves as a key target for vaccine development. By …
-
From Bench To Bedside And Back Again: Car T Cell Signaling And Survival
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingly successful in driving cancer remissions. However, early loss of CAR T cells and return of normal B cells is a predictor of relapse in pediatric acute lymphoblastic leukemia; the duration of …
-
Generation and characterization of CD19 CAR T cells with PD-1_CD28 fusion receptor
… strategy for B-ALL, adoptive T-cell transfer of CD19 targeting T cells with chimeric antigen receptor (CAR) has emerged. Clinical studies show remission rates of heavily pretreated patients of up to 90% upon CAR T-cell infusion. Despite temporary remission, around 50% of patients treated with a …
-
CD28 CO-STIMULATION AND CANCER IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR-MODIFIED NATURAL KILLER CELLS
Adaptive immunotherapy using chimeric antigen receptor (CAR) modified immune cells has shown promising clinical benefits for the treatment of cancer. Among different effector immune cells tested for CAR immunotherapy, natural killer (NK) cells are attractive since they, as opposed to T cells, …
-
Engineered plasma cells: a novel platform for long-term delivery of biologics to treat leukemia and other diseases
… of non-immunoglobulin G (IgG)-like bispecific antibodies by human plasma cells to treat leukemias in vivo; b) a humanized mouse model to assess engraftment function and pharmacokinetics of adoptively transferred autologous ePC; and c) a novel B cell signaling BCR/Ab-screening method to evaluate …
-
Cytoskeletal regulation of B cell antigen receptor signaling
Signaling through the B cell antigen receptor (BCR) is essential for several processes of B cell biology, such as proliferation, differentiation and homeostasis. Accordingly, the signaling events emanating from the BCR have to be tightly regulated in order to ensure an effective immune response and …
-
Generating CAR γδ T Cells for Effective Targeting of B Lymphomas
Chimeric antigen receptor (CAR) T-cell therapy has attracted growing interest in the treatment of various malignancies and represents the most advanced technology to date. This approach involves the use of genetically engineered immune cells expressing a surface receptor, called CAR, that …
-
Investigation of lentiviral vectors incorporating HIV-1 envelopes for their application in human in vivo gene therapy
… To demonstrate functional transgene activity, an anti-CD19 chimeric antigen receptor (CAR) was delivered to CD4+ T cells, resulting in the generation of CAR T cells. These CD4+ CAR T cells exhibited specific cytotoxicity against CD19-expressing cancer cell lines. Finally, HIV-1 enveloped vectors …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
Page 1 of 3